SVB Securities Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
SVB Securities analyst Andrew Berens has maintained an 'Outperform' rating on Viracta Therapeutics (NASDAQ:VIRX), but lowered the price target from $10 to $5.
August 15, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
SVB Securities has maintained an 'Outperform' rating on Viracta Therapeutics, but lowered the price target from $10 to $5.
The news is directly related to Viracta Therapeutics. While the 'Outperform' rating is maintained, the lowering of the price target could potentially impact investor sentiment and the stock's short-term performance. However, the overall impact is neutral as the 'Outperform' rating suggests that the analyst still expects the stock to do better than the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100